Lenalidomide

Evidence Level: L2

Predicted Indications: 4

Lenalidomide

Pharmacist Assessment Report

Lenalidomide: Myeloid leukemia

One-Sentence Summary

Lenalidomide is an oral immunomodulatory drug originally used for plasma cell myeloma, mantle cell lymphoma and myelodysplastic syndrome (MDS). The TxGNN model predicts it may be effective for myeloid leukemia, with 48 clinical trials and 20 publications currently supporting this direction. Most trials are early-phase (Phase 1/2), and no completed Phase 3 trial is available for this indication.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Myeloid leukemia
TxGNN Prediction Score	0.9949
Evidence Level	L2
Canada Market Status	Marketed (marketed DINs on record: at least 20)
Number of DINs	at least 20
Recommended Decision	Proceed with Guardrails (as a research question)

Why is This Prediction Reasonable?

Lenalidomide is a cereblon E3 ligase modulator. It binds cereblon and promotes degradation of the transcription factors IKZF1 and IKZF3, as well as CK1α. It also activates NK and T cells. The CK1α mechanism is well established in MDS with del(5q), a disease closely related to acute myeloid leukemia (AML). A 2025 laboratory study also showed that cereblon levels influence how sensitive AML cells are to lenalidomide.

Lenalidomide is already used in MDS and plasma cell myeloma. MDS is a myeloid neoplasm that often progresses to AML, so the biology is shared. Early trials in AML and high-risk MDS include relapsed/refractory disease, post-remission maintenance, and combinations with azacitidine or standard chemotherapy.

Detailed mechanism-of-action data were not available in the data compiled for this report, so the above reflects established pharmacology. The link is plausible, but clinical proof in AML is still limited.

Clinical Trial Evidence

48 trials were identified. The table lists the 10 most relevant, prioritising trials with a relevance grade of A or B, then larger completed Phase 2/3 studies.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00352001	Phase 1/2	Completed	37	Lenalidomide plus azacitidine in advanced MDS/myeloid malignancies
NCT02126553	Phase 2	Completed	29	Lenalidomide maintenance in high-risk AML in remission
NCT00360672	Phase 2	Completed	27	Single-agent lenalidomide in relapsed/refractory AML or high-risk MDS with chromosome 5 abnormalities
NCT00831766	Phase 1/2	Completed	51	Idarubicin and cytarabine followed by lenalidomide in MDS (RAEB-2) or untreated AML
NCT01681537	Phase 1	Completed	36	Lenalidomide plus mitoxantrone, etoposide, cytarabine (MEC) for AML reinduction; dose-finding and safety
NCT01578954	Phase 1	Completed	20	Dose-finding of lenalidomide as consolidation and maintenance in AML patients 60 or older
NCT01301820	Phase 2	Completed	120	Alternating lenalidomide and azacitidine maintenance after induction in elderly AML
NCT01358734	Phase 2	Completed	88	Randomised comparison of lenalidomide, sequential azacitidine plus lenalidomide, and azacitidine alone in older newly diagnosed AML
NCT01038635	Phase 1/2	Completed	94	Azacitidine plus lenalidomide in high-risk MDS and AML
NCT04490707	Phase 3	Unknown	60	Azacitidine plus lenalidomide maintenance guided by MRD monitoring in elderly or unfit AML; status unverified

Note: the only Phase 3 trials found are NCT04490707 (status unknown, 60 patients) and NCT00843882 (MDS with anemia, still active). Neither is a completed Phase 3 RCT in AML.

Literature Evidence

Most of the retrieved papers are MDS reviews rather than AML-specific trials.

PMID	Year	Type	Journal	Key Findings
23316859	2013	Review	Expert Opin Investig Drugs	Lenalidomide as a novel AML treatment; approved for del(5q) MDS and myeloma, with trials in higher-risk MDS and AML
39881283	2025	Laboratory study	Cell Mol Biol Lett	KDM5C stabilises cereblon and increases AML cell sensitivity to lenalidomide
37288607	2023	Review	Am J Hematol	MDS diagnosis, risk stratification and management update
42400116	2026	Review	Am J Hematol	2026 update on MDS diagnosis and management
41348013	2025	Review	Hematology ASH Educ Program	Updates in low- and intermediate-risk MDS
37874917	2023	Review	Blood	Clinical decision-making in MDS
29795386	2018	Review	Blood Cancer J	Current MDS treatment algorithm
24656536	2014	Review	Lancet	Myelodysplastic syndromes overview; progression to AML in about a third of patients
22483153	2012	Review	Curr Cancer Drug Targets	Novel and emerging drugs for AML
17488990	2007	Review	J Clin Oncol	AML and MDS in older patients

Canada Market Information

20 licences are valid, all single-ingredient products. Dosage form, manufacturer and approved-indication text were not available for these licences. The table lists 5 of them.

DIN	Product Name
02304899	REVLIMID
02304902	REVLIMID
02459418	REVLIMID
02507900	TARO-LENALIDOMIDE
02518597	SANDOZ LENALIDOMIDE

Other products include generics from Reddy, Apotex (APO), Nat, and JAMP.

Cytotoxicity

Lenalidomide is an immunomodulatory antineoplastic agent, not a conventional cytotoxic. It is used for haematological malignancies.

Item	Content
Cytotoxicity Classification	Immunomodulatory / targeted (cereblon E3 ligase modulator)
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Complete blood count with differential, renal function
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Contraindications / risk conditions (from the knowledge graph, not label text): thrombocytopenia, neutropenia, agranulocytosis, pulmonary embolism, impaired renal function, cancer, embryoma. The knowledge graph also flags embryo-related risk, consistent with lenalidomide’s thalidomide-derived pregnancy risk, so confirm this against the label.

Drug Interactions: 100 interactions were found. Major-level interactions include:

Rosuvastatin (Major)
Simvastatin (Major)

Moderate-level interactions include eliglustat and naltrexone. The remaining interactions listed have no severity classification.

Package-insert warnings and contraindications were not available. Please refer to the package insert for full safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale:

The mechanism is well characterised (cereblon-mediated degradation) and early-phase evidence in AML is substantial, with many completed Phase 1/2 and Phase 2 trials. However, there is no completed Phase 3 RCT and the retrieved literature is mostly MDS reviews. Lenalidomide is already marketed in Canada, so access is not a barrier.

To proceed, the following is needed:

Phase 3 or randomised evidence in AML, and published results from the completed Phase 2 trials
Package insert warnings and contraindications from Health Canada
Detailed mechanism-of-action data
A haematological monitoring and risk-management plan, given the myelosuppression and thromboembolism signals
Biomarker-defined populations (for example del(5q)) to identify patients most likely to benefit

Other predicted indications (briefly):

Unclassified MDS (L3): benefit is likely limited to del(5q) subsets. Evidence is a Czech cohort experience and case reports.
Partial deletion of chromosome 5q (L4): the biological basis of the approved MDS use, but it is a biomarker rather than a distinct disease. Best treated as a defined subgroup of MDS and related myeloid neoplasms.
Aregenerative anemia (L3): indirect evidence only; the retrieved literature is mostly myeloma and lymphoma.
Refractory cytopenia of childhood (L3, Hold): only a pediatric Phase 1 study in solid tumors/MDS, which offers dosing and safety data but no efficacy data.
Severe congenital hypochromic anemia with ringed sideroblasts (L5, Hold): no trials or literature and no established mechanistic link.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.